Minireviews
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 527-537
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.527
Table 1 Diagnostic criteria for sarcopenia by various working groups
CriteriaRemarks
European Working Group on Sarcopenia in Older People, 2010[16]1 Low muscle strengthProbable sarcopenia is identified by Criterion 1
2 Low muscle quantity or qualityDiagnosis is confirmed by additional documentation of Criterion 2
3 Low physical performanceSarcopenia is considered severe if all 3 criteria are met
ESPEN Special Interest Group, 2010[18]1 Low muscle massCut-off point should be more than 2 standard deviations below mean value of reference population using young adults of the same sex and ethnic background
2 Walking speed < 0.8 m/s in the 4-min test or reduced performance in functional testFunctional test can be any test used for comprehensive geriatric assessment Both criteria should be present
International Working Group on Sarcopenia, 2011[17]1 Gait speed < 1 m/s 2 Lean mass less than the 20th percentile of values for healthy young adultsBoth criteria should be present
European Working Group on Sarcopenia in Older People, 2018 [2]1 Low muscle massCut-off point should be more than 2 standard deviations below mean value of reference population using healthy young adults of the same ethnic background
2 Low muscle strengtDiagnosis is based on documentation of Criterion 1 plus Criterion 2 or Criterion 3
3 Low physical performance
Society of Sarcopenia, Cachexia and Wasting Disorders, 2011[19]1 Walking speed ≤ 1 m/s or < 400 m during 6-min walkBoth criteria should be present
2 Lean appendicular mass corrected for height squared of more than 2 standard deviations below healthy adults of 20–30 years old of the same ethnic group
Table 2 Summary of long-term survival outcomes in sarcopenic patients in eight studies
Ref.No. of patientsIndicationOperationAssessment of sarcopeniaCut-off points for sarcopeniaOutcomesP value
Peng et al[14], 2012557Pancreatic cancerPD and DPTotal psoas indexLowest quartile of the study cohort3-yr survival, maleSarcopenic: 20.3% Non-sarcopenic: 39.2%< 0.05
3-yr survival, femaleSarcopenic: 26.1% Non-sarcopenic: 40.8%< 0.05
Amini et al[31], 2015763Pancreatic adenocarcinomaPD, DP and TPTotal psoas volume (adjusted for height), total psoas indexCut-off value from Peng et al[14]OSSarcopenia as independent risk factor< 0.001
UV: HR 1.72, 95%CI: 1.36–2.19 MV: HR 1.11, 95%CI: 1.11–1.910.006
Joglekar et al[46], 2015180Pancreatic adenocarcinomaPD and DPTotal psoas indexLowest quartile of the study cohortOSNo significant difference0.44
Okumura et al[45], 2015230Pancreatic adenocarcinomaPD, DP and TPTotal psoas index (measured at umbilical level)Calculated from receiver-operating characteristic curvesMedian OSSarcopenic: 17.7 mo Non-sarcopenic: 33.2 mo< 0.001
DFSSignificantly shorter survival in sarcopenic group< 0.001
Onesti et al[66], 2016270Both benign and malignant conditionsPD, DP, central and TPTotal psoas areaLowest tertile of the study cohortOSSignificantly worse survival for sarcopenic group in females only0.005
Ninomiya et al[67], 2017265Pancreatic adenocarcinomaPD, DP and TPTotal abdominal muscle area (adjusted for height)Cut-off value from Prado et al[39]Median OSSarcopenic: 23.7 mo Non-sarcopenic: 25.8 mo0.185
Van Dijk et al[47], 2017199Cancer of pancreatic head, ampulla, distal bile duct or duodenumPDTotal abdominal muscle area (adjusted for height), radiation attenuation of skeletal muscle at L3Lowest tertile of the study cohortMedian OSNo difference when total abdominal muscle area was comparedNot reported
Significantly shorter survival in patients with low radiation attenuation0.008
Sugimoto et al[68], 2018323Pancreatic adenocarcinomaPD, DP and TPTotal abdominal muscle area (adjusted for height)Cut-off value from Fearon et al[29]OSNo significant difference0.412
DFSNo significant difference0.390
Lowest quartile from study cohortOSNo significant difference0.075
DFSNo significant difference0.172